血清可溶性白细胞介素2受体及基质细胞衍生因子1α动态监测在急性白血病患者病情评估中的应用价值  

Application value of dynamic monitoring of serum soluble interleukin-2 receptor and stromal cell-derived factor 1αin the evaluation of patients with acute leukemia

作　　者：李建兰[1] 乔巨[1] 杨英[1] 徐丽娟[1] 梁志鹏[1] 贾红芳[1] Li Jianlan;Qiao Ju;Yang Ying;Xu Lijuan;Liang Zhipeng;Jia Hongfang(Department of Diagnostic Laboratory,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二医院诊断学实验室,太原030001

出　　处：《白血病．淋巴瘤》2020年第4期232-235,共4页Journal of Leukemia & Lymphoma

基　　金：山西省软科学研究计划(2019041046-3);山西医科大学校级教改课题(XJ2018085)。

摘　　要：目的探讨血清可溶性白细胞介素2受体(sIL-2R)及基质细胞衍生因子1α(SDF-1α)动态监测在急性白血病(AL)患者病情评估中的应用价值。方法选取2017年3月至2018年8月山西医科大学第二医院AL患者187例,另选同期健康体检者90名作为健康对照。于患者初诊期、缓解期、复发期检测血清sIL-2R、SDF-1α水平,分析二者动态监测的临床价值。结果187例AL患者经化疗后完全缓解135例(72.19%),部分缓解52例(27.81%);复发43例(31.85%)。AL患者初诊期血清sIL-2R水平为(533±32)U/ml,高于健康对照者的(247±30)U/ml,差异有统计学意义(t=71.976,P<0.01);AL患者初诊期血清SDF-1α水平为(2968±305)pg/ml,高于健康对照者的(1358±160)pg/ml,差异有统计学意义(t=47.043,P<0.01)。AL患者完全缓解期血清sIL-2R[(308±30)U/ml]、SDF-1α[(1576±184)pg/ml]水平低于初诊期,复发期血清sIL-2R[(599±36)U/ml]、SDF-1α[(2894±301)pg/ml]水平高于完全缓解期(均P<0.01)。结论AL患者血清sIL-2R、SDF-1α水平增高,且初诊期、缓解期、复发期两者水平有较大差异,动态监测二者可为临床早期干预提供数据支持。Objective To explore the application value of dynamic monitoring of serum soluble interleukin-2 receptor(sIL-2R)and stromal cell-derived factor 1α(SDF-1α)in patients with acute leukemia(AL).Methods A total of 187 patients with AL admitted to the Second Hospital of Shanxi Medical University from March 2017 to August 2018 were selected and 90 healthy subjects at the same period were selected as the healthy controls.The levels of serum sIL-2R and SDF-1αwere detected at the initial diagnosis,remission phase and relapse phase,respectively.The clinical value of dynamic monitoring of sIL-2R and SDF-1αwas analyzed.Results Among 187 patients with AL,135 patients(72.19%)had complete remission(CR)after chemotherapy,52 patients(27.81%)had partial remission,and 43 patients(31.85%)relapsed.The level of serum sIL-2R at the AL initial diagnosis period was(533±32)U/ml,which was higher than that in the healthy controls[(247±30)U/ml],and the difference was statistically significant(t=71.976,P<0.01);the level of serum SDF-1αat the AL initial diagnosis was(2968±305)pg/ml,which was higher than that in the healthy controls[(1358±160)pg/ml],and the difference was statistically significant(t=47.043,P<0.01).The levels of serum sIL-2R[(308±30)U/ml]and SDF-1α[(1576±184)pg/ml]in the CR phase were lower than those in the initial diagnosis of patients with AL;and the levels of sIL-2R[(599±36)U/ml]and SDF-1α[(2894±301)pg/ml]in the relapse phase were higher than those in the CR phase of patients with AL(all P<0.01).Conclusions The levels of serum sIL-2R and SDF-1αin patients with AL are increased,and there are big differences in the levels of sIL-2R and SDF-1αat the initial diagnosis,remission phase,and relapse phase.Dynamic monitoring of both can provide the data support for early clinical intervention.

关 键 词：白血病 急性 可溶性白细胞介素2受体 基质细胞衍生因子1Α 

分 类 号：R733[医药卫生—肿瘤]